Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer

Cancer Causes and Control

Volumn 11, Issue 3, 2000, Pages 231-238

  Farrow, Diana C ^a,i   Vaughan, Thomas L ^a   Sweeney, Carol ^a   Gammon, Marilie D ^b   Chow, Wong Ho ^c   Risch, Harvey A ^d   Stanford, Janet L ^a   Hansten, Philip D ^a   Mayne, Susan T ^d   Schoenberg, Janet B ^e   Rotterdam, Heidi ^f   Ahsan, Habibul ^b   West, A Brian ^g   Dubrow, Robert ^d   Fraumeni Jr , Joseph F ^c   Blot, William J ^h  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Division of Epidemiology ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^f Office of Cancer Epidemiology ^*  (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Esophageal neoplasms; Gastric neoplasms; Gastroesophageal reflux disease; H2 receptor antagonists

Indexed keywords

ANTACID AGENT; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; AGED; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH ULCER; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; ANTACIDS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STOMACH NEOPLASMS; STOMACH ULCER; WASHINGTON;

EID: 0034068341     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008913828105     Document Type: Note

References (21)

1. 1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289.
2. 2. Gammon MD, Schoenberg JB, Ahsan H, et al. (1997) Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 89: 1277-1284.
3. 3. Chow W-H, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr (1995) The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274: 474-477.
4. 4. Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825-831.
5. 5. Chow W-H, Blot WJ, Vaughan TL, et al. (1998) Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90: 150-155.
6. 6. Kabat GC, Ng SKC, Wynder EL (1993) Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 4: 123-132.
7. 7. Brown LM, Silverman DT, Pottern LM, et al. (1994) Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 5: 333-340.
8. 8. Vaughan TL, Davis S, Kristal A, Thomas DB (1995) Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 4: 85-92.
9. 9. Vaughan TL, Farrow DC, Hansten PD, et al. (1998) Risk of esophageal and gastric adenocarcinoma in relation to use of calcium channel blockers, asthma drugs and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 7: 749-756.
10. 10. Wang HH, Hsieh CC, Antonioli DA (1994) Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esophageal sphincter (United States). Cancer Causes Control 5: 573-578.
11. 11. Anonymous (1998) Top 200 drugs of 1997. Pharm Times, April.
12. 12. Elder JB, Ganguli PC, Gillespie IE (1979) Cimetidine and gastric cancer. Lancet 1: 1005-1006.
13. 13. Foster AB, Jarman M, Manson D, Schulten HR (1980) Structure and reactivity of nitrosocimetidine. Cancer Lett 9: 47-52.
14. 14. Moller H, Lindvig K, Klefter R, Mosbech J, Moller Jensen O (1989) Cancer occurrence in a cohort of patients treated with cimetidine. Gut 30: 1558-1562.
15. 15. Moller H, Nissen A, Mosbech J (1992) Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. Gut 33: 1166-1169.
16. 16. LaVecchia C, Negri E, Davanzo B, Franceschi S (1990) Histamine-2-receptor antagonists and gastric cancer risk. Lancet 336: 355-357.
17. 17. LaVecchia C, Negri E, Franceschi S, D'Avanzo B (1992) Histamine-2-receptor antagonists and gastric cancer: update and note on latency and covariates. Nutrition 8: 177-181.
18. 18. Colin-Jones DG, Langman MJS, Lawson DH, Logan RFA, Paterson KR, Vessey MP (1991) Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med 78: 13-19.
19. 19. Johnson AG, Jick SS, Perera DR, Jick H (1996) Histamine-2 receptor antagonists and gastric cancer. Epidemiology 7: 434-436.
20. 20. Schumacher MC, Jick SS, Jick H, Feld D (1990) Cimetidine use and gastric cancer. Epidemiology 1: 251-254.
21. 21. Farrow DC, Vaughan TL, Hansten PD, et al. (1998). Use of aspirin and other non-steroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97-102.